Friends
I just posted my review of some pretty promising data on ABT-199 in difficult to treat patients with F refractory or del 17p disease.
Our future is getting more and more interesting.
Brian
ASCO 2013: ABT-199 in relapsed and refractory ... - CLL Support
ASCO 2013: ABT-199 in relapsed and refractory disease
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
ABT-199 Trial experience in Australia
Following are my notes on the presentation by Andrew Roberts, to the Australian Leukaemia...
ABT-199 plus Obinutuzimab
Finally remembered my login! Just a quick note to let you know I started the trial today at Barts...
Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients
This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the...
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
Oncology live May 06, 2020
The time-limited triplet of umbralisib, ublituximab, and venetoclax...
Related Posts
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
- Scottish Medicines Consortium approves Venetoclax + Rituximab Treatment for relapsed/refractory CLL
- Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis
- BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
- Results of Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory CLL
